A0596 - First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations von Vilaseca, A., Jayram, G., Raventos, C., Shore, N.D., Zainfeld, D., Kang, T.W., Ku, J.H., Meeks, J., Rodríguez Faba, O., Roghmann, F., Daneshmand, S., Beeharry, N., Cost, C.R., Kalota, A., Lauring, J., Peterson, M.R., Quiroz, M.Q., Stone, N.L., Zhu, W., Gurrero-Ramos, F.

Volltext

First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations von Vilaseca, A., Jayram, G., Raventos, C., Shore, N.D., Zainfeld, D., Kang, T.W., Ku, J.H., Meeks, J., Rodríguez Faba, O., Roghmann, F., Daneshmand, S., Beeharry, N., Cost, C.R., Kalota, A., Lauring, J., Peterson, M.R., Quiroz, M.Q., Stone, N.L., Zhu, W., Gurrero-Ramos, F.

Volltext